Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When a stock trading at 46 cents. I really can not dream a buyout price at price a lot higher than $4+.
I don't agree with your perspective. Look at the hiring activity at Advent. Close to 100 people now and they continue to add more people. LP pouring money into that to be prepared for UK approvals. And that’s the right thing to do.
She still has a bunch of C shares at her disposal and hiring around dozen folks on the commercial front is not going to break the bank, a few months before approval.
The signs are clearly pointing towards a big pharma partnership deal on GBM sales and additional combo trial(s) whether you like it or not. A big non dilutive cash injection is coming.
ATLnsider - Overall we're on the same page.
Tooo funny, I forgot about that one. There are many well educated and tolerant individuals on this board… but when it comes to these lying pricks I’ve had enough! At least everyone should know they are hired mercenaries.
NOTICE HOW IT WON’T DENY THEIR ROLES IN WRITING!
This post-MHRA environment would need to include full approval and NICE coverage not some conditional or partial scheme.
Of course nemesis is paid
Answer the question… ARE YOU PAID TO POST FUD ON NWBO?
Hey Inquiriq: Are you compensated in any way to post FUD on NWBO?
You are paid to post FUD here, aren’t you?
Ilovetech, I agree that waiting for lawsuits to be settled, is not part of NWBio’s business strategy. You and I do not disagree on this fact.
I never said NWBio is waiting on the lawsuits to settle, before they execute their business strategy. The lawsuits will have an eventual outcome, separate and apart from NWBio executing it strategic business objectives.
NWBio is focused on executing its strategic business plan, and that includes achieving milestones, beginning with DCVax-L approval by MHRA in the UK, and combination partnerships, and approval of the Flasksworks devices, and approval of DCVax-L in the US, Canada and the EU.
None of this changes the facts that NWBio is currently a non-revenue producing company, with no commercially approved product(s), and very limited Cash to go out and hire a salesforce.
Same, just. Same.
Wait and see, I continue buying, lowest recently around .50.
Not fussed it's lower now, I'll keep buying bits and pieces. Hell, I've put in anywhere from 300 bucks to 10k in various transactions.
300 at .5 is 600+ shares, 600 shares, even just at 3 bucks is 1,800.00
That's another solid ebike. 👌
The major holding remains, that's for a lakehouse. Storing a boat at the marina drives me crazy, it should be viewed from my back window. Hope is alive and well.
Zadie420 - Now that's a bit drastic for a forward looking statement. My confidence in getting to a much higher valuation than the number you're suggesting is simply because, it's LP running the show. As much as I'm incensed regarding the daily unchecked criminal enterprise, I remain focused on the big picture. The best defense is having a strong offense.
Today I slightly modified my order from a limit price of $0.46 to $0.4603, no luck to get fill until close to market close for only 6k shares. Talking is cheap, we only have diminished days to add this cheap. I plan to intensify my accumulation as price becomes more attractive.
At least a safe and efficacious treatment is good for humanity, then that will be good for regulators as well. Doesn't matter when approval will happen.
LOL. Come on! You know you'll be posting just like you are today. You're one of those committed to holding to zero.
>>Now if we are still this price in late May or early June 2024, then that is time to start talking about manipulation or at least be concerned there's some hidden shoe yet to drop that smart money knows about, because by that time, FOMO should start kicking in.
Great comments HL! Perspective always helps… added 120k shares Monday and just beginning to wonder if I should be question my sanity! I believe & know we’ve won but waiting for the trophy seems like an eternity.
In this 3 minute round table interview with Bernie Madoff, you could just as easily insert the market makers he references:
Unless you think there is some hidden piece of news that is driving the drop, it's not really unsettling, just enervating.
I am taking advantage of this extended buying opportunity to buy in bits and pieces without breaking the bank, deferring credit card payments or doing anything else that is foolish. I've been able to substantially increase my position and a couple of days ago I bought at about 50 cents and now its 47 cents. So what? If my investing thesis is right, I'll be way past that, not to begrudge 3 cents here or there. If my investing thesis is wrong, I should get out now (I don't think I'm wrong, not in the medium run, anyway).
The market (which appears to consist mainly of existing retailers) seems to pricing in the idea that approval is not happening in April 2024 and probably won't happen in May 2024 so there is no FOMO that is causing people to mortgage their houses, get payday loans, borrow money, sell other 'quality' stocks etc. to raise large amounts to buy.
We've just had way too many 'last chances to buy cheap' for anyone to get excited here.
So, in the absence of news, and with Captain Obvious' share counter continuing to go up as NWBO gets money to keep the lights on, why would the price stay stable?
Instead, the share price will slowly get pulled down by gravity and while it might be buffeted briefly upward, with the absence of news, the tendency is to settle towards the ground.
Now if we are still this price in late May or early June 2024, then that is time to start talking about manipulation or at least be concerned there's some hidden shoe yet to drop that smart money knows about, because by that time, FOMO should start kicking in.
Ilovetech- I am afraid nothing is going on now. The mgt is waiting for approval as simple as that. How do I know well they just announced it in the last Q report. This slow period was best opportunity for the company to ink a combo trial.
Actually by announcing this piece of information to all it allowed MMS attacking the pps. Not smart if you ask me. How much percentage we have lost since January 1st.
Oh by the way we know the negotiations was going on since last June for combo trail. Almost one year.
Sometimes we have to accept the defeat. All these manipulation was driven by big pharma. We cannot even do multitasking at this stage. Company needs to be sold around $4+. Let someone take this wonderful platform to another level.
Dcavax-d won’t add that much to MC since it has been gathering dust.
Given that the individual who started this is not supporting their position with hard facts combined with informed speculation on what MHRA approval is likely to do for the SP, I would agree with you.
Someone who discusses the issue with facts and informed speculation about the post-MHRA environment, can on the other hand, have a valid discussion of this issue, even now. To say otherwise would be to rule a sober discussion of other topics like revenues to be out-of-bounds until MHRA approval, in which case, we wouldn't be left with much to read.
Non management staying silent is killing nwbo. Some things never change. Are they silent because they fucked up submission??? Would not suprise me. They really do not know how to communicate.
ATLnsider - The point isn't why NWBO can't afford to hire sales, but rather, it's what the circumstances are that needs to shape the company strategy. You haven't said anything that isn't obvious, especially for someone in LP's position. How many milestones and subsequent sp losses do you think it took, before LP began putting a strategy together, which likely doesn't include hiring sales? Waiting for the courts is not a business strategy. If you want to understand what hiring a Salesforce entails, take a look at the company's 10K. I was actually very surprised at how candid the company was, and how detailed it was in describing its shortcomings, as being a risk to undertake. Obviously, finances were part of it, but not the driver of the disclaimer.
HL if we were post MHRA approval and this is where we stood it might be a real concern but it’s not. Talking about a reverse split pre-MHRA approval is fear mongering for the ignorant stray readers who happen upon this chat room.
I disagree with the idea that it is guaranteed to come, but I believe that the possibility that it is likely to happen can only be dismissed with evidence and reasoning showing how other courses besides an R/S would be more expedient for management than an R/S. Just dismissing the concern based on who is perceived as raising it is a weak argument given the history of the company turning to this tool.
A comparison of an R/S vs other strategies for getting the price high enough for uplisting could be explored with the pros and cons enumerated. So too could the benefits of deferring uplisting until we have profits rolling in.
<<< Possibly their thinking is a lower price today will translate to a lower buyout price, if that were to happen. >>>
Possibly your thinking would have Sigmund Freud confused and considering a new career path?
Good informative post. Yep, that's why you almost certainly know it's coming now. They couldn't do last time around when they instead got the vote just to increase authorized.
>>will cause us to swallow the R/S without a murmur.
Price drop is unsettling, but application for approval has been submitted and its allready being used in compassionate care cases for years. makes no sense.
Yes, and that someone might be your fearless CEO, who has been printing shares like Kinkos. !!!!!
Just opining here and spitballing a bit
Possibly, but LP has her price and it would have to be major collusion among mult BPs.. Just trying to make sense of it. If one BP were behind keeping price low, wouldnt they be afraid some competition would jump in and scoop up shares? There definitely is price manipulation going on, but all the reasons posted dont really make sense if you think about it. At .50 a share, all remaining shares should have been scooped up by BPs , especially merck. The daily average volume does not point to major buying interest. Unless HFs are keeping price low to counter lawsuit argument that price should be much higher. But again, no volume means no SP improvement.
kfa670 I wanted to do the same, but funds have not cleared yet (thank goodness). When funds do clear will take another look at it. Want to increase my position but this price drop is very unsettling.
Give us a break …. Awareness about short squeeze . That has been discussed on this board for a decade . People have designed their yachts based on mother of all short squeezes on this board in last 10 years again and again . It is discussed in virtually every development stage companies board by people who are dreaming about overnight billionaires .
You are making it sound like a well kept secret .
Did you notice my question mark at the end? "?"
Do do know what that symbol represents????? ???? ???? ????
ummmm, responding to a pump post is not creating fear, uncertainty, or doubt, just keeping it real
Someone wants to make sure NWBO close at low every single day. Watch last 15-30 minutes. you will see.
Possibly their thinking is a lower price today will translate to a lower buyout price, if that were to happen.
Enough already with the fake excuses....
04/23/24 - 1,204,236,917
04/20/24 - 1,204,039,742
04/17/24 - 1,203,973,067
04/12/24 - 1,203,199,607
04/11/24 - 1,201,099,732
04/10/24 - 1,200,500,107
04/06/24 - 1,199,672,730
04/05/24 - 1,198,812,505
04/03/24 - 1,197,237,455
03/28/24 - 1,195,269,485
03/27/24 - 1,194,274,786
03/26/24 - 1,193,493,852
03/19/24 - 1,193,316,128
03/15/24 - 1,193,166,128
03/14/24 - 1,192,908,369
03/10/24 - 1,192,237,685
03/07/24 - 1,190,170,308
02/29/24 - 1,189,970,308
02/27/24 - 1,188,836,983
02/22/24 - 1,188,731,708
02/17/24 - 1,187,812,280
02/14/24 - 1,186,753,180
02/13/24 - 1,186,425,305
01/30/24 - 1,185,680,827
01/27/24 - 1,185,128,327
01/25/24 - 1,182,971,840
01/24/24 - 1,182,454,590
01/23/24 - 1,182,433,108
01/19/24 - 1,181,833,108
01/09/24 - 1,181,176,418
01/04/24 - 1,175,459,031
01/03/24 - 1,173,563,502
2023:
12/23/23 - 1,172,382,472
01/06/23 - 1,061,044,165
2023 Detail:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173492032
2022:
12/21/22 - 1,058,132,006
01/22/22 - 949,180,606
2022 Detail:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170751056;
2021:
12/31/21 - 947,621,531
01/12/21 - 822,825,147
2020:
12/31/20 - 822,716,397
01/27/20 - 625,187,160
Shorts short to keep the price down, so their mark-to-market naked/legal short liabilities don't blow up in their face. It will blow up on them regardless, very soon, and upon approval, but the shorts are trying to manage that. That is the basic premise. Your response of why shorts would continue to short and statements that they do short as defying logic seems to be an insincere response.
But I do understand why shorts would not want the shorting topic to go on right before MHRA approval. It is because that opens up the awareness and possibility for a major short squeeze to happen. That is the short's worse fear. That fear was also my response to the original question of "Why would they be keeping price down for a buyout?" To be clear though and as a long investor, shorting is a secondary or third level matter of importance as well, as MHRA approval and adoption are the key drivers going forward.
So... My post got one (1) legitimate response and FOUR (4) fudster comments.
Yes, 7 years but there's a rumor that the 8th year is a charmer.
.
<<< Especially with supposed good news coming. >>>
"Contradictions do not exist. Whenever you think you are facing a contradiction, check your premises. You will find that one of them is wrong."
~ Ayn Rand
Silence is the stock killer, and silence is what nwbo management is good at. Another shitty day.
Especially with supposed good news coming. Another bloodbath on the way down the .40's.
The old "reverse split" BS rearing its ugly fud head every 2 months. Desperation FUD since every science argument has been countered
As I've said before, never have I seen one where the CEO CFO Chair hasn't publicly presented or had a quarterly call in a year let alone over five years! And, I can't ever recall one where the CEO CFO Chair owned the CDMO. Maybe they'll surprise me. LOL
NWBio is not hiring new sales and management teams now, because they cannot afford to do that now. It’s as simple as that.
NWBio does not have enough cash or capital to go on a hiring spree now, because their common stock has been illegally manipulated, spoofed and shorted for over a decade, by a collusive cabal of Market Makers, Hedge Funds, Short Sellers, corrupt financial and biotech “journalists”, and their illicit and hired social media surrogates who post lies and misinformation about NWBio and DCVax 24/7/365 for over a decade.
NWBio has been forced to sell its common shares for pennies over the past decade. This will all be sorted out eventually in both civil and criminal courts in the future.
According to its most recent 10-K, as of December 31, 2023, Day One Biotherapeutics had over $376 million in Cash, Cash Equivalents and other liquid and Current Assets. Compared to NWBio, who only had about $4.1 million.
With over $376 million in Cash, it is very easy for Day One Biotherapeutics to go out and hire teams of new employees. They are flushed with Cash, Not so much for NWBio.
I understand grabbing shares to cover naked shorts before buyout, but not keeping price down "for" a buyout.
Holy Moly $0.46 cents at the close.!
and tote bags are new design, ...just stop allready
Followers
|
1621
|
Posters
|
|
Posts (Today)
|
115
|
Posts (Total)
|
689026
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |